|Christoph Male, MD, MSc
Department of Pediatrics and Adolescent Medicine
Medical University of Vienna, Austria
At the end of this session, the participants should:
Educational needs addressed:
Hospital pharmacists need to have insights into the new pediatric clinical data and the respective new indication of rivaroxaban. Furthermore, hospital pharmacists need to be informed about effective anticoagulation with rivaroxaban across all indications in children and adults, including high-risk vulnerable patients with cardiovascular diseases to ensure optimal pharmaceutical care for anticoagulated patients.
For further questions